[go: up one dir, main page]

AR117918A1 - COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS - Google Patents

COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS

Info

Publication number
AR117918A1
AR117918A1 ARP200100240A ARP200100240A AR117918A1 AR 117918 A1 AR117918 A1 AR 117918A1 AR P200100240 A ARP200100240 A AR P200100240A AR P200100240 A ARP200100240 A AR P200100240A AR 117918 A1 AR117918 A1 AR 117918A1
Authority
AR
Argentina
Prior art keywords
tgfb
inhibitors
specific
ltbp
complex
Prior art date
Application number
ARP200100240A
Other languages
English (en)
Inventor
Adam Fogel
Christopher Littlefield
Stefan Wawersik
Abhishek Datta
George Coricor
Justin W Jackson
Thomas Schurpf
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69423073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR117918(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of AR117918A1 publication Critical patent/AR117918A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento se describen inhibidores, tales como anticuerpos, y porciones de unión a antígeno de los mismos, que se unen selectivamente a complejos de LTBP1-TGFb y/o LTBP3-TGFb. La aplicación también proporciona métodos de uso de estos inhibidores para, por ejemplo, inhibir la activación de TGFb y tratar sujetos que padecen trastornos relacionados con TGFb, tales como afecciones fibróticas. También se proporcionan métodos para seleccionar un inhibidor de TGFb específico de isoforma dependiente de contexto o independiente de contexto para un sujeto que lo necesite.
ARP200100240A 2019-01-30 2020-01-30 COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS AR117918A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962798927P 2019-01-30 2019-01-30

Publications (1)

Publication Number Publication Date
AR117918A1 true AR117918A1 (es) 2021-09-01

Family

ID=69423073

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100240A AR117918A1 (es) 2019-01-30 2020-01-30 COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS

Country Status (22)

Country Link
US (4) US11214614B2 (es)
EP (1) EP3689905A3 (es)
JP (2) JP7724712B2 (es)
KR (1) KR20210121174A (es)
CN (1) CN113677711B (es)
AR (1) AR117918A1 (es)
AU (1) AU2020216177A1 (es)
BR (1) BR112021015056A2 (es)
CA (1) CA3128042A1 (es)
CL (1) CL2021001993A1 (es)
CO (1) CO2021010062A2 (es)
CR (1) CR20210416A (es)
DO (1) DOP2021000161A (es)
EA (1) EA202192130A1 (es)
IL (1) IL285076A (es)
MA (1) MA54845A (es)
MX (1) MX2021009175A (es)
PE (1) PE20220279A1 (es)
PH (1) PH12021551860A1 (es)
SG (1) SG11202108099WA (es)
TW (1) TW202043267A (es)
WO (1) WO2020160291A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658583A1 (en) 2017-07-28 2020-06-03 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
AR117918A1 (es) 2019-01-30 2021-09-01 Scholar Rock Inc COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS
BR112022003412A2 (pt) 2019-08-28 2022-05-24 Chugai Pharmaceutical Co Ltd Anticorpos anti-tgf-beta 1 latente de espécies cruzadas e métodos de uso
WO2021142427A1 (en) * 2020-01-11 2021-07-15 Scholar Rock, Inc. TGFβ INHIBITORS AND USE THEREOF
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
US20250319117A1 (en) * 2021-06-03 2025-10-16 The University Of Chicago Methods and compositions for treating fibrosis
IL309078A (en) * 2021-06-23 2024-02-01 Scholar Rock Inc A myostatin pathway inhibitor in combination with a GLP-1 pathway activator for use in the treatment of metabolic disorders
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
EP4638496A1 (en) 2022-12-22 2025-10-29 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
EP4676954A1 (en) 2023-03-07 2026-01-14 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
WO1992015677A1 (en) 1991-03-01 1992-09-17 Protein Engineering Corporation Process for the development of binding mini-proteins
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US7803553B2 (en) 2003-09-04 2010-09-28 Riken Methods of use of antibodies which recognize a protease cleavage site of an LAP fragment of TGF-β
AU2006213875B2 (en) 2005-02-08 2010-08-19 Genzyme Corporation Antibodies to TGFBETA
EA016038B1 (ru) 2005-04-22 2012-01-30 Эли Лилли Энд Компани Антитело к tgf-бета и его применение
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
WO2011102483A1 (ja) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
DK2714735T3 (da) * 2011-06-03 2021-10-18 Xoma Technology Ltd Antistoffer, der er specifikke for TGF-beta
SG10201704616SA (en) 2012-11-06 2017-07-28 Scholar Rock Inc Compositions and methods for modulating cell signaling
EP3816625B1 (en) * 2013-05-06 2025-09-17 Scholar Rock, Inc. Compositions and methods for growth factor modulation
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
CN116327915A (zh) 2015-04-03 2023-06-27 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
JP7107836B2 (ja) * 2015-09-15 2022-07-27 スカラー ロック インコーポレイテッド 抗プロ／潜在型ミオスタチン抗体およびその使用
FI3365368T3 (fi) 2016-03-11 2023-06-13 Scholar Rock Inc Tgf-beeta-1:tä sitovia immunoglobuliineja ja niiden käyttö
US10946036B2 (en) 2016-06-13 2021-03-16 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
IL264161B2 (en) 2016-07-14 2025-06-01 Scholar Rock Inc Tgfb antibodies, methods, and uses
US10375984B2 (en) 2016-07-18 2019-08-13 R.J. Reynolds Tobacco Company Nonwoven composite smokeless tobacco product
SG11201901126UA (en) 2016-08-12 2019-03-28 Merck Patent Gmbh Combination therapy for cancer
WO2018043734A1 (en) * 2016-09-05 2018-03-08 Chugai Seiyaku Kabushiki Kaisha Anti-tgf-beta 1 antibodies and methods of use
US20180207267A1 (en) 2017-01-06 2018-07-26 Scholar Rock, Inc. Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
AU2018205233A1 (en) 2017-01-07 2019-07-11 Merck Patent Gmbh Dosing regimens and dosage forms for targeted TGFβ inhibition
WO2018134681A1 (en) 2017-01-20 2018-07-26 Sanofi Anti-tgf-beta antibodies and their use
CN110573532B (zh) 2017-03-02 2024-04-16 加拿大国家研究委员会 TGF-β 受体胞外域融合分子及其用途
EP3658583A1 (en) * 2017-07-28 2020-06-03 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
BR112021000353A2 (pt) 2018-07-11 2021-08-03 Scholar Rock, Inc. inibidores de tgfb1 de alta afinidade, isoforma-seletivos, e seus usos
US20210340238A1 (en) 2018-07-11 2021-11-04 Scholar Rock, Inc. TGFß1 INHIBITORS AND USE THEREOF
AR117918A1 (es) 2019-01-30 2021-09-01 Scholar Rock Inc COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS

Also Published As

Publication number Publication date
SG11202108099WA (en) 2021-08-30
BR112021015056A2 (pt) 2022-01-11
MA54845A (fr) 2021-09-29
CL2021001993A1 (es) 2022-04-08
WO2020160291A9 (en) 2020-10-15
PH12021551860A1 (en) 2022-05-16
JP7724712B2 (ja) 2025-08-18
CN113677711A (zh) 2021-11-19
TW202043267A (zh) 2020-12-01
US20250179164A1 (en) 2025-06-05
DOP2021000161A (es) 2021-09-15
IL285076A (en) 2021-09-30
MX2021009175A (es) 2021-09-14
EA202192130A1 (ru) 2021-12-28
CA3128042A1 (en) 2020-08-06
US20220064276A1 (en) 2022-03-03
CR20210416A (es) 2021-09-14
EP3689905A2 (en) 2020-08-05
US11214614B2 (en) 2022-01-04
US20210047396A1 (en) 2021-02-18
JP2025172758A (ja) 2025-11-26
WO2020160291A2 (en) 2020-08-06
US11365245B2 (en) 2022-06-21
JP2022524281A (ja) 2022-05-02
AU2020216177A1 (en) 2021-09-23
KR20210121174A (ko) 2021-10-07
EP3689905A3 (en) 2021-02-24
US20220363741A1 (en) 2022-11-17
US12173059B2 (en) 2024-12-24
PE20220279A1 (es) 2022-02-25
WO2020160291A3 (en) 2020-09-10
CO2021010062A2 (es) 2021-08-09
CN113677711B (zh) 2025-05-30

Similar Documents

Publication Publication Date Title
AR117918A1 (es) COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
CL2021003190A1 (es) Inhibidores de tead y usos de los mismos
CO2022008407A2 (es) Anticuerpos específicos para cd47, pd–l1 y sus usos
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
CL2019000508A1 (es) Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados.
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
MX2019005277A (es) Composiciones de celulas t con car anti-bcma.
MX390385B (es) Anticuerpos anti-pd-l1.
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
CO7111273A2 (es) Anticuerpos cd47 y métodos de uso de los mismos
CO2019009612A2 (es) Proteinas de unión a antígeno anti-tigit y métodos de uso de las mismas
UY37258A (es) AGENTES REVERSORES DE UNIÓN PARA ANTICUERPOS ANTI-FACTOR XI/XIa Y SUS USOS
CL2019002232S1 (es) Automóvil.
CL2020001201S1 (es) Automóvil.
CL2023003694A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
DOP2021000113A (es) Anticuerpos antiperiostina y usos de estos
MX2016016507A (es) Composiciones y metodos para tratar canceres.
CL2020000224S1 (es) Automóvil.
EA202090309A1 (ru) Анти-tigit антитела
DOP2025000178A (es) Agentes que se unen a nkg2a y pd-l1 y usos de estos
AR117578A1 (es) Anticuerpos específicos para cd3 y sus usos
EP4445210A4 (en) ATTACHMENT SYSTEM FOR PORTABLE DEVICES
UY4762U (es) Forros adherentes para zapatos
CL2019002603S1 (es) Automóvil.